News SCOTUS Overturns Roe vs Wade, Leaving Many Women Without Access to Abortion Publish Date June 27, 2022
News Zulresso Indication Expanded to Include Younger Patients With Postpartum Depression By Brian Park, PharmD Publish Date June 21, 2022
News Post Hoc Analysis Shows Phexxi Prevented 99% of Pregnancies Per Act of Intercourse By Brian Park, PharmD Publish Date June 16, 2022
Drugs in the Pipeline FDA to Review Data on Long-Term Use of Myfembree for Uterine Fibroids By Brian Park, PharmD Publish Date June 3, 2022
News FDA Extends Shelf Life of On-Demand Contraceptive Phexxi By Brian Park, PharmD Publish Date June 2, 2022
Drugs in the Pipeline Trial Evaluating Zuranolone for Postpartum Depression Meets All Endpoints By Brian Park, PharmD Publish Date June 1, 2022
News At-Home Test Helps With Birth Control Selection by Identifying Risk for Side Effects By Brian Park, PharmD Publish Date May 24, 2022
News Annovera Product Supply Expected to Increase Following FDA Approval By Brian Park, PharmD Publish Date May 20, 2022
Features Beyond Hysterectomy: Increasing Awareness of Uterine Fibroids and New Treatment Options By Nicholas Zittell Publish Date May 16, 2022
News Serotonergic Antidepressants in Pregnancy Not Tied to Neonatal Seizures Publish Date May 13, 2022
Drugs in the Pipeline FDA Extends Review Period for Relugolix Combo Therapy for Endometriosis Pain By Brian Park, PharmD Publish Date May 9, 2022
News Vivjoa Approved for Recurrent Vulvovaginal Candidiasis By Brian Park, PharmD Publish Date April 28, 2022